<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548012" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548012/" /><meta name="ncbi_pagename" content="Baricitinib - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Baricitinib - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Baricitinib" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2020/12/02" /><meta name="citation_pmid" content="31643344" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548012/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Baricitinib" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2020/12/02" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548012/" /><meta name="description" content="Baricitinib is an orally available small molecule inhibitor of Janus kinases that is used to treat moderate-to-severe rheumatoid arthritis and more recently was given emergency use authorization as therapy in combination with remdesivir for severe COVID-19. Baricitinib is associated with transient and usually mild elevations in serum aminotransferase levels during therapy but has yet to be linked to cases of clinically apparent acute liver injury." /><meta name="og:title" content="Baricitinib" /><meta name="og:type" content="book" /><meta name="og:description" content="Baricitinib is an orally available small molecule inhibitor of Janus kinases that is used to treat moderate-to-severe rheumatoid arthritis and more recently was given emergency use authorization as therapy in combination with remdesivir for severe COVID-19. Baricitinib is associated with transient and usually mild elevations in serum aminotransferase levels during therapy but has yet to be linked to cases of clinically apparent acute liver injury." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548012/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Baricitinib/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548012/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8A2E9104654B910000000008A70268.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548012_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548012_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Barbiturates/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Basiliximab/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548012_"><span class="title" itemprop="name">Baricitinib</span></h1><p class="small">Last Update: <span itemprop="dateModified">December 2, 2020</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Baricitinib.OVERVIEW"><h2 id="_Baricitinib_OVERVIEW_">OVERVIEW</h2><div id="Baricitinib.Introduction"><h3>Introduction</h3><p>Baricitinib is an orally available small molecule inhibitor of Janus kinases that is used to treat moderate-to-severe rheumatoid arthritis and more recently was given emergency use authorization as therapy in combination with remdesivir for severe COVID-19. Baricitinib is associated with transient and usually mild elevations in serum aminotransferase levels during therapy but has yet to be linked to cases of clinically apparent acute liver injury.</p></div><div id="Baricitinib.Background"><h3>Background</h3><p>Baricitinib (bar" i sye' ti nib) is an orally available, specific inhibitor Janus-associated kinases (mainly JAK1 and JAK2) that is used to treat moderate-to-severe rheumatoid arthritis. The Janus kinases are critical steps in immune activation as well as in hematopoiesis. JAK1 is a critical kinase in the cellular responses of interferon alpha while JAK2 is involved in pathways activated by interferon gamma. The immunomodulatory effects of baricitinib have led to its evaluation in several autoimmune conditions including rheumatoid arthritis and psoriasis. In multiple randomized controlled trials, baricitinib was found to improve symptoms and signs of severe rheumatoid arthritis when used alone or in combination with other disease modifying anti-rheumatologic drugs (DMARDs). Baricitinib was approved for use in the United States in 2018, the third small molecule JAK inhibitor to receive approval (after tofacitinib in 2012 and ruxolitinib in 2011). Formal indications for baricitinib are limited to adults with moderate-to-severe rheumatoid arthritis after failure or intolerance to anti-tumor necrosis factor agents with or without non-biological DMARDs. Baricitinib is also under evaluation as therapy for other autoimmune conditions including psoriasis and atopic dermatitis. Baricitinib is available in tablets of 2 mg under the brand name Olumiant. The recommended dose in rheumatoid arthritis is 2 mg once daily. Common side effects are nausea, diarrhea, fatigue, neutropenia, cholesterol and creatinine elevations, herpes simplex and zoster infections, and symptoms of upper respiratory tract infection. Severe adverse events may include severe infections, reactivation of latent tuberculosis, increased risk of malignancy, gastrointestinal perforation and vascular thromboses.</p><p>In November 2020, baricitinib was given emergency use authorization in combination with remdesivir as therapy of adults and children above the age of 2 who are hospitalized with confirmed COVID-19 infection and require supplementary oxygen, mechanical ventilation or extracorporeal mechanical oxygenation. Preliminary trials of baricitinib in patients with severe COVID-19 pneumonia given in combination with remdesivir suggested that it shortened the time to recovery and reduced morbidity. Further trials are in progress to confirm and extend these results. The recommended dose regimen in adults is 4 mg orally once daily for 14 days or until hospital discharge.</p></div><div id="Baricitinib.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>In the large prelicensure clinical trials in rheumatoid arthritis, serum aminotransferase elevations occurred in up to 17% of baricitinib treated subjects compared to 11% in placebo recipients. These elevations were typically mild and transient and values above 5 times the upper limit of normal (ULN) occurred in &#x0003c;1% of patients on baricitinib. The elevations occasionally led to early discontinuations, but more often resolved even without dose adjustment. In prelicensure studies in rheumatoid arthritis and other rheumatic and immune-mediated disorders, there were no instances of clinically apparent liver injury attributed to baricitinib. Since approval and more wide scale availability of baricitinib, there have been no published reports of hepatotoxicity associated with its use.</p><p>Use of baricitinib in combination with remdesivir for severe COVID-19 pneumonia has been reported in only small case series with little information on its potential for causing liver injury. Patients with severe SARS-CoV-2 infection frequently have elevated serum aminotransferase levels and occasionally are jaundiced. Furthermore, remdesivir has been linked to serum aminotransferase elevations during therapy that are generally mild-to-moderate in severity and resolve rapidly once the drug is stopped. Whether baricitinib increases the risk of liver injury during COVID-19 has yet to be shown but hepatotoxicity was not a prominent feature in preliminary studies.</p><p>Finally, baricitinib is an immune modulatory agent and has the potential of causing reactivation of viral infections including hepatitis B. In clinical trials, patients with HBsAg in serum were excluded from enrollment but patients with anti-HBc without HBsAg were allowed. While routine monitoring for reactivation was not performed on all patients, at least 15% of anti-HBc positive persons with rheumatoid arthritis treated with baricitinib developed virologic evidence of reactivation marked by de novo appearance of low levels of HBV DNA in serum. In all cases, the period of viremia was brief and not associated with serum aminotransferase elevations or jaundice. Thus, baricitinib appears to be capable of causing HBV reactivation but it is generally subclinical.</p><p>Likelihood score: E* (unlikely to be a cause of idiosyncratic clinically apparent liver injury but has the potential to cause reactivation of hepatitis B).</p></div><div id="Baricitinib.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The cause of mild serum enzyme elevations during baricitinib therapy is not known. Baricitinib is largely excreted unchanged in urine and stool and less than 10% undergoes hepatic metabolism, largely via CYP 3A4. The metabolism of baricitinib is not affected by CYP inhibitors or inducers, but its renal excretion can be affected by probenecid.</p></div><div id="Baricitinib.Outcome_and_Management"><h3>Outcome and Management</h3><p>Monitoring of serum aminotransferase levels is recommended for patients starting baricitinib. De novo elevations in serum aminotransferases levels above 5 times the upper limit of normal should lead to temporary cessation. If serum enzyme elevations do not resolve or improve within a few weeks of stopping, or if symptoms of liver injury or jaundice arise, baricitinib should be permanently discontinued. There does not appear to be cross reactivity in risk for hepatic injury between baricitinib and tofacitinib or other biologic or non-biologic DMARDs. Because of its potential to cause reactivation of hepatitis B, routine screening for HBsAg and anti-HBc is appropriate before starting therapy with baricitinib and patients with HBsAg in serum should be monitored carefully for early evidence of reactivation or receive prophylaxis with antivirals with activity against HBV, such as tenofovir or entecavir.</p><p>Drug Class: <a href="/books/n/livertox/AntirheumaticAgents/">Antirheumatic Agents</a>, <a href="/books/n/livertox/ProteinKinaseInhibit/">Protein Kinase Inhibitors</a></p></div></div><div id="Baricitinib.PRODUCT_INFORMATION"><h2 id="_Baricitinib_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Baricitinib &#x02013; Olumiant&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Antirheumatic Agents</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?label=all&#x00026;query=Baricitinib" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="Baricitinib.CHEMICAL_FORMULAS_AND_STRUCT"><h2 id="_Baricitinib_CHEMICAL_FORMULAS_AND_STRUCT_">CHEMICAL FORMULAS AND STRUCTURES</h2><div id="Baricitinib.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548012/table/Baricitinib.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Baricitinib.Tc_lrgtbl__"><table><thead><tr><th id="hd_h_Baricitinib.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_h_Baricitinib.Tc_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NO.</th><th id="hd_h_Baricitinib.Tc_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Baricitinib.Tc_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Baricitinib.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Baricitinib</td><td headers="hd_h_Baricitinib.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/162108950" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">1187594-09-7</a></td><td headers="hd_h_Baricitinib.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C16-H17-N7-O2-S</td><td headers="hd_h_Baricitinib.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/162108950" title="View this structure in PubChem" class="img_link" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&amp;sid=162108950" alt="image 162108950 in the ncbi pubchem database" /></a></td></tr><tr><td headers="hd_h_Baricitinib.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tofacitinib</td><td headers="hd_h_Baricitinib.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135253188" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">477600-75-2</a></td><td headers="hd_h_Baricitinib.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C16-H20-N6-O</td><td headers="hd_h_Baricitinib.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135253188" title="View this structure in PubChem" class="img_link" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&amp;sid=135253188" alt="image 135253188 in the ncbi pubchem database" /></a></td></tr></tbody></table></div></div></div><div id="Baricitinib.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Baricitinib_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 02 December 2020</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Baricitinib.REF.zimmerman.1999">Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999.<div><i>(Review of hepatotoxicity published in 1999 before the availability of protein kinase inhibitors such as tofacitinib and baricitinib).</i></div></div></li><li><div class="bk_ref" id="Baricitinib.REF.deleve.2013">DeLeve LD. Erlotinib. Cancer chemotherapy. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 556.<div><i>(Review of hepatotoxicity of cancer chemotherapeutic agents; discusses several kinase inhibitors including imatinib, gefitinib, erlotinib and crizotinib, but not baricitinib).</i></div></div></li><li><div class="bk_ref" id="Baricitinib.REF.wellstein.2018">Wellstein A, Giaccone G, Atkins MB, Sausville EA. Pathway-targeted therapies: monoclonal antibodies, protein kinase inhibitors, and various small molecules. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman &#x00026; Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 1203-36.<div><i>(Textbook of pharmacology and therapeutics; baricitinib is not discussed specifically).</i></div></div></li><li><div class="bk_ref" id="Baricitinib.REF.fda">FDA. <a href="https://www.accessdata.fda.gov/scripts/cder/daf/" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">https://www<wbr style="display:inline-block"></wbr>​.accessdata<wbr style="display:inline-block"></wbr>​.fda.gov/scripts/cder/daf/</a><div><i>(FDA Drug Approvals website that has product labels [package inserts], letters of approval and full FDA scientific review of the new drug application for safety and efficacy).</i></div></div></li><li><div class="bk_ref" id="Baricitinib.REF.van_vollenhoven.2012.508">van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garc&#x000ed;a Meijide JA, Wagner S, Forejtova S, et al. ORAL Standard Investigators.  Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. <span><span class="ref-journal">N Engl J Med. </span>2012;<span class="ref-vol">367</span>:508–19.</span> [<a href="/pubmed/22873531" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22873531</span></a>]<div><i>(Among 717 patients with rheumatoid arthritis on methotrexate treated with tofacitinib [5 or 10 mg] or adalimumab or placebo for 52 weeks, clinical response rates were higher for tofacitinib [52-53%] than placebo [28%] and adverse events were more common [with two cases of pulmonary tuberculosis]; ALT elevations during the first 3 months occurred in 26% on tofacitinib vs 17% on placebo).</i></div></div></li><li><div class="bk_ref" id="Baricitinib.REF.fleischmann.2012.495">Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, Gruben D, et al. ORAL Solo Investigators.  Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. <span><span class="ref-journal">N Engl J Med. </span>2012;<span class="ref-vol">367</span>:495–507.</span> [<a href="/pubmed/22873530" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22873530</span></a>]<div><i>(Among 611 patients with rheumatoid arthritis treated with tofacitinib [5 or 10 mg] or placebo twice daily for 3 months, clinical response rates were higher with tofacitinib, and adverse events included headache, infections, neutropenia and increases in serum cholesterol; ALT elevations above 3 times ULN occurred during the first 3 months in &#x0003c;1% of both groups).</i></div></div></li><li><div class="bk_ref" id="Baricitinib.REF.shah.2013.491">Shah RR, Morganroth J, Shah DR. Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. <span><span class="ref-journal">Drug Saf. </span>2013;<span class="ref-vol">36</span>:491–503.</span> [<a href="/pubmed/23620168" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23620168</span></a>]<div><i>(Review of the hepatotoxicity of 18 tyrosine kinase inhibitors approved for use in cancer in the US as of 2013; baricitinib and tofacitinib are not discussed).</i></div></div></li><li><div class="bk_ref" id="Baricitinib.REF.spraggs.2013.541">Spraggs CF, Xu CF, Hunt CM. Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors. <span><span class="ref-journal">Pharmacogenomics. </span>2013;<span class="ref-vol">14</span>:541–54.</span> [<a href="/pubmed/23556451" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23556451</span></a>]<div><i>(Review of genetic associations of serum ALT and bilirubin elevations during therapy with tyrosine kinase inhibitors focusing on lapatinib and pazopanib; baricitinib and tofacitinib is not mentioned).</i></div></div></li><li><div class="bk_ref" id="Baricitinib.REF.keystone.2015.333">Keystone EC, Taylor PC, Drescher E, Schlichting DE, Beattie SD, Berclaz PY, Lee CH, et al.  Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. <span><span class="ref-journal">Ann Rheum Dis. </span>2015;<span class="ref-vol">74</span>:333–40.</span> [<a href="/pmc/articles/PMC4316868/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4316868</span></a>] [<a href="/pubmed/25431052" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25431052</span></a>]<div><i>(Among 301 patients with rheumatoid arthritis and an inadequate response to methotrexate treated with baricitinib [1, 2, 4 or 8 mg] or placebo daily for 12 weeks, clinical response rates were higher with the higher doses of baricitinib, while rates of ALT elevations were similar in all groups and no patient suffered a liver related serious adverse event).</i></div></div></li><li><div class="bk_ref" id="Baricitinib.REF.papp.2015.949">Papp KA, Menter MA, Abe M, Elewski B, Feldman SR, Gottlieb AB, Langley R, et al.  OPT Pivotal 1 and OPT Pivotal 2 investigators. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. <span><span class="ref-journal">Br J Dermatol. </span>2015;<span class="ref-vol">173</span>:949–61.</span> [<a href="/pubmed/26149717" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26149717</span></a>]<div><i>(Among 1861 patients with plaque psoriasis treated with tofacitinib [5 or 10 mg] or placebo twice daily for 16 weeks, higher rates of improvement occurred with tofacitinib [42% to 59%] than placebo [9% to 11%], while adverse event rates were similar overall; ALT elevations above 3 times ULN occurred in 0.6% vs 0.2% of patients).</i></div></div></li><li><div class="bk_ref" id="Baricitinib.REF.genovese.2016.1243">Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, Beattie SD, et al.  Baricitinib in patients with refractory rheumatoid arthritis. <span><span class="ref-journal">N Engl J Med. </span>2016;<span class="ref-vol">374</span>:1243–52.</span> [<a href="/pubmed/27028914" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27028914</span></a>]<div><i>(Among 527 patients with rheumatoid arthritis refractory to tumor necrosis factor inhibitors who were treated with baricitinib [2 or 4 mg] or placebo daily for 24 weeks, clinical response rates were higher with baricitinib as were adverse events [61% and 67% vs 55%], including mild and transient ALT elevations [14% and 17% vs 10%], but no patient developed ALT elevations over 5 times ULN or suffered a liver related serious adverse event).</i></div></div></li><li><div class="bk_ref" id="Baricitinib.REF.papp.2016.1266">Papp KA, Menter MA, Raman M, Disch D, Schlichting DE, Gaich C, Macias W, et al.  A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. <span><span class="ref-journal">Br J Dermatol. </span>2016;<span class="ref-vol">174</span>:1266–76.</span> [<a href="/pubmed/26800231" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26800231</span></a>]<div><i>(Among 271 patients with plaque psoriasis treated with baricitinib [2, 4, 8 or 10 mg] or placebo daily for 12 weeks, clinical responses were more frequent with baricitinib, particularly with higher doses while adverse event rates [including ALT elevations] were similar in all groups).</i></div></div></li><li><div class="bk_ref" id="Baricitinib.REF.markham.2017.697">Markham A. Baricitinib: first global approval. <span><span class="ref-journal">Drugs. </span>2017;<span class="ref-vol">77</span>:697–704.</span> [<a href="/pubmed/28290136" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28290136</span></a>]<div><i>(Review of the development of baricitinib, its clinical efficacy and safety mentions that of 3464 patients treated in prelicensure clinical trials 6% developed adverse events leading to drug discontinuation, 3.4% developed herpes zoster, 3.2% serious infections, 0.7% malignancies and 0.3% died; aminotransferase elevations arose in 1.4% of patients but &#x0201c;most cases were transient&#x0201d;).</i></div></div></li><li><div class="bk_ref" id="Baricitinib.REF.taylor.2017.652">Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, Reyes Gonzaga J, et al.  Baricitinib versus placebo or adalimumab in rheumatoid arthritis. <span><span class="ref-journal">N Engl J Med. </span>2017;<span class="ref-vol">376</span>:652–62.</span> [<a href="/pubmed/28199814" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28199814</span></a>]<div><i>(Among 1307 patients with rheumatoid arthritis receiving methotrexate, addition of baricitinib led to higher clinical response rates than did adalimumab or placebo, while adverse event rates were higher with active therapies and ALT elevations arose in 27% on baricitinib, 24% on adalimumab vs 17% on placebo, but were above 5 times ULN in 1% or less in all three groups).</i></div></div></li><li><div class="bk_ref" id="Baricitinib.REF.dougados.2017.88">Dougados M, van der Heijde D, Chen YC, Greenwald M, Drescher E, Liu J, Beattie S, et al.  Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. <span><span class="ref-journal">Ann Rheum Dis. </span>2017;<span class="ref-vol">76</span>:88–95.</span> [<a href="/pmc/articles/PMC5264214/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5264214</span></a>] [<a href="/pubmed/27689735" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27689735</span></a>]<div><i>(Among 684 patients with rheumatoid arthritis refractory to DMARDs treated with baricitinib [2 or 4 mg] or placebo daily for 24 weeks, clinical response rates were higher with baricitinib while serious adverse event rates were similar, although mean changes in ALT levels were greater with baricitinib [+6 U/L] and adalimumab [+5 U/L] than with placebo [+1 U/L]).</i></div></div></li><li><div class="bk_ref" id="Baricitinib.REF.fleischmann.2017.506">Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M, Zerbini CA, et al.  Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. <span><span class="ref-journal">Arthritis Rheumatol. </span>2017;<span class="ref-vol">69</span>:506–17.</span> [<a href="/pmc/articles/PMC5347954/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5347954</span></a>] [<a href="/pubmed/27723271" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27723271</span></a>]<div><i>(Among 588 patients with rheumatoid arthritis treated with baricitinib or methotrexate or the combination, clinical response rates were highest in patients receiving baricitinib while ALT elevations arose in 33% on methotrexate alone, 16% on baricitinib alone and 34% on both, but ALT values above 5 times ULN were rare occurring in 1% or less and there were no hepatic severe adverse events).</i></div></div></li><li><div class="bk_ref" id="Baricitinib.REF.sanchez.2018.3041">Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, Schalm S, et al.  JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. <span><span class="ref-journal">J Clin Invest. </span>2018;<span class="ref-vol">128</span>:3041–52.</span> [<a href="/pmc/articles/PMC6026004/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6026004</span></a>] [<a href="/pubmed/29649002" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29649002</span></a>]<div><i>(Among 18 patients with various interferon mediated autoinflammatory conditions treated with baricitinib for an average of 3 years, all except 5 had marked improvements in clinical symptoms and signs; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Baricitinib.REF.keystone.2018.14">Keystone EC, Genovese MC, Schlichting DE, de la Torre I, Beattie SD, Rooney TP, Taylor PC. Safety and efficacy of baricitinib through 128 weeks in an open-label, longterm extension study in patients with rheumatoid arthritis. <span><span class="ref-journal">J Rheumatol. </span>2018;<span class="ref-vol">45</span>:14–21.</span> [<a href="/pubmed/28811354" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28811354</span></a>]<div><i>(Among 301 patients enrolled in a controlled trial of baricitinib [2, 4, or 8 mg daily] for 24 weeks [Keystone 2015], 171 entered an open label extension study [4 or 8 mg daily], and 133 completed 128 weeks of treatment, among whom ALT elevations occurred in approximately 25% but were above 5 times ULN in 1% or less; one patient developed a self-limited acute hepatitis B that was apparently nosocomially acquired and unrelated to therapy).</i></div></div></li><li><div class="bk_ref" id="Baricitinib.REF.guttmanyassky.2019.913">Guttman-Yassky E, Silverberg JI, Nemoto O, Forman SB, Wilke A, Prescilla R, et al.  Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. <span><span class="ref-journal">J Am Acad Dermatol. </span>2019;<span class="ref-vol">80</span>(4):913–921.e9.</span> [<a href="/pubmed/29410014" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29410014</span></a>]<div><i>(Among 124 adults with atopic dermatitis treated with baricitinib [2 or 4 mg] or placebo daily for 16 weeks, clinical response rates were higher with baricitinib [57% and 61% vs 37%] as were adverse event rates [46% and 71% vs 49%]; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Baricitinib.REF20">Drugs for rheumatoid arthritis. <span><span class="ref-journal">Med Lett Drugs Ther. </span>2018;<span class="ref-vol">60</span>(1552):123–8.</span> [<a href="/pubmed/30044766" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30044766</span></a>]<div><i>(Review of drugs for rheumatoid arthritis mentions that baricitinib is an orally available, small molecule inhibitor of JAK kinases and that its potential adverse side effects include serum ALT elevations).</i></div></div></li><li><div class="bk_ref" id="Baricitinib.REF21">Baricitinib (olumiant) for rheumatoid arthritis. <span><span class="ref-journal">Med Lett Drugs Ther. </span>2018;<span class="ref-vol">60</span>(1551):120–1.</span> [<a href="/pubmed/30036348" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30036348</span></a>]<div><i>(Concise review of the mechanism of action, clinical efficacy and safety of baricitinib shortly after its approval for use in rheumatoid arthritis in the US, mentions that elevations in liver enzymes have been reported to occur).</i></div></div></li><li><div class="bk_ref" id="Baricitinib.REF.wallace.2018.222">Wallace DJ, Furie RA, Tanaka Y, Kalunian KC, Mosca M, Petri MA, D&#x000f6;rner T, et al.  Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. <span><span class="ref-journal">Lancet. </span>2018;<span class="ref-vol">392</span>:222–31.</span> [<a href="/pubmed/30043749" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30043749</span></a>]<div><i>(Among 314 adults with systemic lupus erythematosus treated with baricitinib [2 or 4 mg] or placebo once daily for 24 weeks, clinical improvements arose in 53% on placebo versus 58% and 67% on baricitinib while adverse events were more frequent with study drug; while there were no &#x0201c;clinically meaningful differences in laboratory abnormalities&#x0201d;, ALT levels above 3 times ULN arose in 1.9% on placebo versus 4.8% on 4 mg but none on 2 mg of baricitinib daily, and there were no severe hepatic adverse events).</i></div></div></li><li><div class="bk_ref" id="Baricitinib.REF.smolen.2019.7">Smolen JS, Genovese MC, Takeuchi T, Hyslop DL, Macias WL, Rooney T, Chen L, et al.  Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment. <span><span class="ref-journal">J Rheumatol. </span>2019;<span class="ref-vol">46</span>:7–18.</span> [<a href="/pubmed/30219772" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30219772</span></a>]<div><i>(Analysis of adverse effects of baricitinib in 8 controlled trials and one long term extension study of rheumatoid arthritis included data on 3492 patients followed for a median of 2.1 years found an increased rate of infections with baricitinib 2 mg and 4 mg daily vs placebo [84 and 88.4 vs 75.9 per 100 patient-yrs], 10 cases of tuberculosis [all with 4 mg daily] and increased rate of herpes zoster [3.1 and 4.3 vs 1.0 per 100 patient-years]; no mention of ALT elevations or hepatotoxicity: see Winthrop 2020).</i></div></div></li><li><div class="bk_ref" id="Baricitinib.REF.richardson.2020.e30">Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, Rawling M, et al.  Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. <span><span class="ref-journal">Lancet. </span>2020;<span class="ref-vol">395</span>(10223):e30–e31.</span> [<a href="/pmc/articles/PMC7137985/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC7137985</span></a>] [<a href="/pubmed/32032529" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 32032529</span></a>]<div><i>(Using artificial intelligence, pathways of SARS-CoV-2 were defined and agents known to inhibit those enzymes were sought, an impressive candidate being baricitinib which inhibits AAK1 which mediates the transfer of SARS-CoV19 ).</i></div></div></li><li><div class="bk_ref" id="Baricitinib.REF.harigai.2020.e001095">Harigai M, Winthrop K, Takeuchi T, Hsieh TY, Chen YM, Smolen JS, Burmester G, et al.  Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis. <span><span class="ref-journal">RMD Open. </span>2020;<span class="ref-vol">6</span>(1):e001095. </span> [<a href="/pmc/articles/PMC7046961/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC7046961</span></a>] [<a href="/pubmed/32098857" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 32098857</span></a>]<div><i>(Among 215 patients with anti-HBc without HBsAg treated with baricitinib [2 or 4 mg daily] in preregistration trials, 32 developed detectable HBV DNA during treatment, but levels were low (usually less than 100 IU/mL, transient and not associated with ALT elevations, symptoms or jaundice).</i></div></div></li><li><div class="bk_ref" id="Baricitinib.REF.winthrop.2020.1290">Winthrop KL, Harigai M, Genovese MC, Lindsey S, Takeuchi T, Fleischmann R, Bradley JD, et al.  Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. <span><span class="ref-journal">Ann Rheum Dis. </span>2020;<span class="ref-vol">79</span>:1290–7.</span> [<a href="/pubmed/32788396" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 32788396</span></a>]<div><i>(Analysis of adverse effects of baricitinib in 8 controlled trials and one long term extension study of in rheumatoid arthritis included data on 3492 patients followed for a median of 2.6 years found an increased rate of infections with baricitinib 2 mg and 4 mg daily vs placebo [84 and 88.4 vs 75.9 per 100 patient-yrs], 11 cases of tuberculosis [all with 4 mg daily] and increased rate of herpes zoster [3.1 and 4.3 vs 1.0 per 100 patient-years]; no mention of ALT elevations or hepatotoxicity: see Smolen 2019 ).</i></div></div></li><li><div class="bk_ref" id="Baricitinib.REF.peng.2020.1505">Peng L, Xiao K, Ottaviani S, Stebbing J, Wang YJ. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib. <span><span class="ref-journal">Expert Opin Drug Saf. </span>2020;<span class="ref-vol">19</span>:1505–11.</span> [<a href="/pubmed/32693646" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 32693646</span></a>]<div><i>(Analysis of the FDA Adverse Event Reporting System from 2018 to 2020 identified 1598 reports on baricitinib, the topic area reporting odds ratio [ROR] being highest and statistically significant for infections [n=464, ROR = 3.0] and hepatobiliary disorders [n=84, ROR = 2.0] which included specific terms of hepatocellular injury in 17, cholestasis 7, hepatitis 7, liver injury 5 and steatosis 5).</i></div></div></li><li><div class="bk_ref" id="Baricitinib.REF.raschi.2020.1367">Raschi E, Caraceni P, Poluzzi E, De Ponti F. Baricitinib, JAK inhibitors and liver injury: a cause for concern in COVID-19? <span><span class="ref-journal">Expert Opin Drug Saf. </span>2020;<span class="ref-vol">19</span>(10):1367–9.</span> [<a href="/pubmed/32840116" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 32840116</span></a>]<div><i>(Letter in response to Peng et al [2020] stressing the need to assess the potential hepatotoxicity of baricitinib in human trials).</i></div></div></li><li><div class="bk_ref" id="Baricitinib.REF.jorgensen.2020.843">Jorgensen SCJ, Tse CLY, Burry L, Dresser LD. Baricitinib: a review of pharmacology, safety, and emerging clinical experience in COVID-19. <span><span class="ref-journal">Pharmacotherapy. </span>2020;<span class="ref-vol">40</span>:843–56.</span> [<a href="/pmc/articles/PMC7323235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC7323235</span></a>] [<a href="/pubmed/32542785" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 32542785</span></a>]<div><i>(Review of the mechanisms of action and potential antiviral and anticytokine actions of baricitinib that make it a candidate therapy for COVID-19 including its inhibition of pathways in interferon alpha signaling and cytokine induction; mentions that serum aminotransferase elevations have been reported in humans receiving baricitinib for SARS-CoV-2 infection).</i></div></div></li><li><div class="bk_ref" id="Baricitinib.REF.titanji.2020">Titanji BK, Farley MM, Mehta A, Connor-Schuler R, Moanna A, Cribbs SK, O'Shea J, et al. Use of baricitinib in patients with moderate and severe COVID-19. Clin Infect Dis 2020 Jun 29: ciaa879. Epub ahead of print. [<a href="/pmc/articles/PMC7337637/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC7337637</span></a>] [<a href="/pubmed/32597466" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 32597466</span></a>]<div><i>(Among 15 patients hospitalized with severe COVID-19 treated with hydroxychloroquine and baricitinib [2 or 4 mg daily] for an average of 5 days [range 1 to 7], 12 improved and 3 died; no mention of hepatic complications; ALT levels averaged 52 U/L before [range 16-126] vs 68 U/L after [range 13-180] therapy).</i></div></div></li><li><div class="bk_ref" id="Baricitinib.REF.sodani.2020.101115">Sodani P, Mucci L, Girolimetti R, Tedesco S, Monaco F, Campanozzi D, Brunori M, et al.  Successful recovery from COVID-19 pneumonia after receiving baricitinib, tocilizumab, and remdesivir. A case report: Review of treatments and clinical role of computed tomography analysis. <span><span class="ref-journal">Respir Med Case Rep. </span>2020;<span class="ref-vol">31</span>:101115. </span> [<a href="/pmc/articles/PMC7320265/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC7320265</span></a>] [<a href="/pubmed/32670785" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 32670785</span></a>]<div><i>(50 year old man with severe COVID-19 pneumonia was treated initially with hydroxychloroquine and azithromycin followed by baricitinib and then tocilizumab and corticosteroids, and finally remdesivir, after which there was slow but steady recovery).</i></div></div></li><li><div class="bk_ref" id="Baricitinib.REF.reich.2020.1333">Reich K, Kabashima K, Peris K, Silverberg JI, Eichenfield LF, Bieber T, Kaszuba A, et al.  Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. <span><span class="ref-journal">JAMA Dermatol. </span>2020;<span class="ref-vol">156</span>(12):1333–43.</span> [<a href="/pmc/articles/PMC7527941/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC7527941</span></a>] [<a href="/pubmed/33001140" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 33001140</span></a>]<div><i>(Among 329 adults with atopic dermatitis treated with baricitinib [2 or 4 mg daily] vs placebo for 16 weeks, itching decreased with baricitinib therapy, and no patient had ALT elevations greater than 3 times ULN during therapy).</i></div></div></li><li><div class="bk_ref" id="Baricitinib.REF.bieber.2020">Bieber T, Thyssen JP, Reich K, Simpson EL, Katoh N, Torrelo A, De Bruin-Weller M, et al.  Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. <span><span class="ref-journal">J Eur Acad Dermatol Venereol. </span>2020 Sep 14;</span> In Press. [<a href="/pubmed/32926462" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 32926462</span></a>]<div><i>(Analysis of safety data from 6 controlled trials and 3 extension studies of baricitinib in 2531 patients with atopic dermatitis found no greater rates of severe infections or opportunistic infections but slight increase in rates of herpes zoster with baricitinib compared to placebo therapy; ALT elevations of 3 times ULN or above occurred in 1.0% of placebo vs 1.6% of baricitinib treated subjects and was above 5 times ULN in 0.1% vs 0.2%, one treated subject having ALT levels above 10 times ULN, but none with clinically apparent liver injury with jaundice).</i></div></div></li><li><div class="bk_ref" id="Baricitinib.REF.reich.2020.1">Reich K, DeLozier AM, Nunes FP, Thyssen JP, Eichenfield LF, Wollenberg A, Ross Terres JA, et al.  Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials. <span><span class="ref-journal">J Dermatolog Treat. </span>2020 Nov 22;:1–10.</span> [<a href="/pubmed/33222559" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 33222559</span></a>]<div><i>(Combined analysis of 2 randomized controlled trials of baricitinib [2 or 4 mg] versus placebo is 1239 adults with atopic dermatitis reported decreases in severity of itch and skin pain and improvements in sleep and quality of life with baricitinib compared to placebo in both trials; no discussion of adverse events or ALT levels).</i></div></div></li><li><div class="bk_ref" id="Baricitinib.REF.stebbing.2020.eabe4724">Stebbing J, S&#x000e1;nchez Nievas G, Falcone M, Youhanna S, Richardson P, Ottaviani S, Shen JX, et al.  JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. <span><span class="ref-journal">Sci Adv. </span>2020 Nov 13;:eabe4724. </span> Epub ahead of print. [<a href="/pmc/articles/PMC7775747/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC7775747</span></a>] [<a href="/pubmed/33187978" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 33187978</span></a>]<div><i>(Among 83 patients hospitalized with COVID-19 and treated with baricitinib in 2 European centers who were propensity matched with 83 controls from the same centers and time period, death or need for mechanical ventilation occurred in 17% of baricitinib vs 35% of control subjects, the effect being seen within 5 days and persisting after treatment; ALT elevations above 2 times ULN arose in 15 [18%] but were self-limited and not associated with symptoms or jaundice; in vitro studies demonstrated that baricitinib prevented interferon alfa-induced increased gene expression and increase in SARS-CoV-2 receptor, suggesting an antiviral as well as anti-cytokine effect).</i></div></div></li><li><div class="bk_ref" id="Baricitinib.REF.valorm_ndez.2020">Valor-M&#x000e9;ndez L, Voskens C, Rech J, Kleyer A, Schett G. Herpes simplex infection in a patient with rheumatoid arthritis treated with baricitinib: a case report. Rheumatology (Oxford) 2020 Nov 3: keaa521. Epub ahead of print. [<a href="/pubmed/33141876" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 33141876</span></a>]<div><i>(56 year old woman with rheumatoid arthritis in remission on methotrexate and baricitinib for 1 year stopped therapy for 1 week for elective surgery and then developed severe herpes simplex shortly after restarting and was switched to abatacept and methotrexate after acyclovir therapy and recovery).</i></div></div></li><li><div class="bk_ref" id="Baricitinib.REF.rodriguezgarcia.2020">Rodriguez-Garcia JL, Sanchez-Nievas G, Arevalo-Serrano J, Garcia-Gomez C, Jimenez-Vizuete JM, Martinez-Alfaro E. Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study. Rheumatology (Oxford) 2020 Oct 6: keaa587. Epub ahead of print. [<a href="/pmc/articles/PMC7665718/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC7665718</span></a>] [<a href="/pubmed/33020836" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 33020836</span></a>]<div><i>(Among 387 patients with moderate-to-severe COVID-19 pneumonia treated with methylprednisolone with [n=117] or without baricitinib [n=270], of which 62 receiving baricitinib had more rapid improvements in pulse oximetry-measured oxygen saturation than did a matched group of 50 receiving corticosteroids alone but without differences in rates of ICU admission or death; no mention of hepatotoxicity or ALT elevations).</i></div></div></li><li><div class="bk_ref" id="Baricitinib.REF.fda_1">FDA. <a href="https://www.fda.gov/media/143823/download" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">https://www<wbr style="display:inline-block"></wbr>​.fda.gov/media<wbr style="display:inline-block"></wbr>​/143823/download</a>.<div><i>(FDA fact sheet on use of baricitinib in combination with remdesivir for severe COVID-19 based upon an Emergency Use Authorization of November 19, 2020, with information on indications, drug dosage, adverse events, recommendations for monitoring and management of complications).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548012</span><span class="label">PMID: <a href="/pubmed/31643344" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31643344</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Barbiturates/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Basiliximab/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548012&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548012/?report=reader">PubReader</a></li><li><a href="/books/NBK548012/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548012" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548012" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Baricitinib. [Updated 2020 Dec 2].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548012/pdf/Bookshelf_NBK548012.pdf">PDF version of this page</a> (127K)</li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=Baricitinib+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Baricitinib: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=Baricitinib" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Baricitinib: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4856008" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4856008" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4856008" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31643187" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Tofacitinib</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Tofacitinib<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/32015973" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Palmoplantar Pustulosis-like Eruption Induced by Baricitinib for Treatment of Rheumatoid Arthritis.</a><span class="source">[Eur J Case Rep Intern Med. 2020]</span><div class="brieflinkpop offscreen_noflow">Palmoplantar Pustulosis-like Eruption Induced by Baricitinib for Treatment of Rheumatoid Arthritis.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Koumaki D, Koumaki V, Lagoudaki E, Bertsias G. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Eur J Case Rep Intern Med. 2020; 7(1):001383. Epub 2019 Dec 19.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/33211457" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Remdesivir</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Remdesivir<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/32367507" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment.</a><span class="source">[Drug Saf. 2020]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Veeravalli V, Dash RP, Thomas JA, Babu RJ, Madgula LMV, Srinivas NR. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Drug Saf. 2020 Aug; 43(8):711-725. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31643662" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Fostamatinib</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Fostamatinib<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31643344" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31643344" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class="&#10;                        HTOn&#10;                    "><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T14:19:30-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal103&amp;ncbi_phid=CE8A2E9104654B910000000008A70268&amp;ncbi_session=CE8A2E9104678C01_2215SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548012%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548012&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548012/&amp;ncbi_pagename=Baricitinib - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8A2E9104678C01_2215SID /projects/books/PBooks@9.2 portal103 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>